Shares of NeoGenomics, Inc. (NASDAQ:NEO) have been assigned a consensus recommendation of “Buy” from the seven brokerages that are covering the firm, Market Beat reports. One investment analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $9.50.

NeoGenomics (NASDAQ:NEO) opened at 7.01 on Monday. The firm has a 50-day moving average price of $6.73 and a 200 day moving average price of $6.94. NeoGenomics has a 52-week low of $4.14 and a 52-week high of $8.48. The stock’s market capitalization is $423.05 million.

NeoGenomics (NASDAQ:NEO) last posted its quarterly earnings data on Tuesday, March 1st. The company reported ($0.03) EPS for the quarter, missing the Zacks’ consensus estimate of $0.02 by $0.05. The firm had revenue of $27.30 million for the quarter, compared to the consensus estimate of $26.46 million. The business’s revenue was up 9.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.02 earnings per share. On average, equities research analysts predict that NeoGenomics will post ($0.29) EPS for the current year.

In other news, Director Alison L. Hannah bought 10,000 shares of the stock in a transaction dated Thursday, March 3rd. The stock was bought at an average price of $6.90 per share, for a total transaction of $69,000.00. Following the completion of the acquisition, the director now directly owns 11,560 shares in the company, valued at approximately $79,764. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Oort Douglas M. Van sold 450,000 shares of the stock in a transaction dated Wednesday, March 9th. The shares were sold at an average price of $7.10, for a total transaction of $3,195,000.00. Following the completion of the sale, the chief executive officer now owns 2,125,000 shares of the company’s stock, valued at approximately $15,087,500. The disclosure for this sale can be found here.

A hedge fund recently raised its stake in NeoGenomics stock. Summit Creek Advisors increased its stake in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 51.7% during the fourth quarter, Holdings Channel reports. The fund owned 808,601 shares of the company’s stock after buying an additional 275,551 shares during the period. Summit Creek Advisors’ holdings in NeoGenomics were worth $6,364,000 as of its most recent filing with the SEC.

Several research firms have weighed in on NEO. Zacks Investment Research upgraded shares of NeoGenomics from a “hold” rating to a “buy” rating and set a $7.50 price objective on the stock in a report on Wednesday, March 16th. Benchmark Co. began coverage on shares of NeoGenomics in a report on Friday, March 11th. They set a “buy” rating and a $8.00 price objective on the stock. BTIG Research restated a “buy” rating and set a $9.00 price objective on shares of NeoGenomics in a report on Thursday, March 3rd. Finally, Janney Montgomery Scott began coverage on shares of NeoGenomics in a report on Thursday, January 7th. They set a “buy” rating and a $11.00 price objective on the stock.